Evaluating the SUBLOCADE Treatment Exit Strategy
Completed · NCT05878210
Conditions: Opioid Use Disorder
At a glance
- Research payments reported, 2025
- $22,573
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 12
About the trial
- Sponsor
- Indivior Inc.
- Dates
- Started 2023-11-24; completion 2025-05-09
- Results posted
- Not yet
The purpose of this study is to observe and assess the successful taper and opioid withdrawal experience after participants stop receiving SUBLOCADE because their healthcare provider determines their disease symptoms have been controlled for at least 9 months and they, together with their healthcare provider, plan to discontinue MOUD.
From ClinicalTrials.gov, last updated 2026-01-22. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Indivior Inc. reported $22,573 in research payments for this study in 2025 (26 payments).
Products named: Sublocade
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kristen B. Silvia, MD Addiction Medicine · Portland, ME
- Amanda L. Finney, DO Internal Medicine · Binghamton, NY
- Gita -. Pujari II, M.D. Addiction Medicine · Oklahoma City, OK
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- United Health Services Hospitals, Inc, NY $11,000
- Mainehealth Maine Medical Center, ME $9,073
- Pahl Pharmaceutical Professionals LLC $2,500
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.